Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Norgine

More Like This

PR Newswire associated0

Norgine strengthens rare disease portfolio with acquisition of Theravia

PR Newswire associated0

Norgine completes acquisition of Theravia

PR Newswire associated0

Norgine Announces Appointment of New CEO Janneke van der Kamp

PR Newswire associated0

Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection

PR Newswire associated0

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

PR Newswire associated0

Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

PR Newswire associated0

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

PR Newswire associated0

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma